Thermopylae Holdings Ltd. is 10% Owner at AbCellera Biologics Inc. (ABCL). They have made 13 open-market trades across 1 company since 2021, most recently 2026-02-27.
CIK 0001834449
12 open-market purchases totalling $37.9M since 2021, against 1 sale. Across 12 scored buys the stock is up 23.7% at ninety days, and 19.8 points ahead of the S&P over the same stretch.
12 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ABCL | 56,134,097 | $694.7M |
Shares reported on the most recent Form 4, priced at the 2026-03-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 33% | 75% |
| Avg Move | +0.9% | +2.9% | +23.7% |
| Alpha | +1.8% | +5.8% | +19.8% |
| Scored | 12 | 12 | 12 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABCL | BUY | 2026-02-27 | 2026-03-02 | $3.44 | $131K | -5.6% | -4.2% | +75.8% |
| ABCL | BUY | 2026-02-26 | 2026-02-27 | $3.27 | $580K | +5.2% | -5.2% | +65.4% |
| ABCL | BUY | 2025-03-11 | 2025-03-11 | $2.16 | $1.5M | +6.1% | -10.0% | +9.1% |
| ABCL | BUY | 2024-08-29 | 2024-08-29 | $2.61 | $1.5M | +3.1% | -0.4% | +14.9% |
| ABCL | BUY | 2023-05-26 | 2023-05-26 | $6.52 | $2.0M | +3.5% | -0.1% | -20.5% |
| ABCL | BUY | 2022-12-16 | 2022-12-20 | $10.10 | $1.7M | -9.7% | -3.3% | -28.0% |
| ABCL | BUY | 2022-08-19 | 2022-08-22 | $11.46 | $2.3M | -0.2% | -7.8% | +26.8% |
| ABCL | BUY | 2022-06-13 | 2022-06-15 | $8.03 | $1.0M | +13.1% | +16.2% | +18.4% |
| ABCL | BUY | 2022-06-06 | 2022-06-08 | $7.50 | $968K | +15.7% | +36.6% | +23.3% |
| ABCL | BUY | 2022-05-13 | 2022-05-17 | $7.26 | $2.2M | -0.3% | +16.9% | +71.0% |
| ABCL | BUY | 2022-05-12 | 2022-05-16 | $6.41 | $18.1M | -6.3% | +15.9% | +69.3% |
| ABCL | BUY | 2021-11-11 | 2021-11-15 | $14.76 | $6.0M | -14.2% | -20.3% | -41.7% |
| ABCL | SELL | 2021-06-09 | 2021-06-10 | $24.03 | $134.5M | -13.3% | -26.8% | -28.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.